Bayer buys cell therapy investment BlueRock for up to $600mm
Bayer AG fully acquired privately held cell therapeutics developer BlueRock Therapeutics, paying $240mm in cash up front for 59.2% of the company it did not already own, and pledging another $360mm in development milestones. Including Bayer’s previous investment, BlueRock is valued at $1bn.
- Gene Therapy, Cell Therapy
- Acquisition of Private Biotech
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.